EGFR and non-small cell lung carcinoma: The results showed that in the first-line treatment of EGFR mutation-positive advanced NSCLC, the median PFS in the bevacizumab plus erlotinib combination treatment group was 17.9 months, and the median PFS in the erlotinib monotherapy group was 11.2 months (65).